

Christopher J Rhodes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4771251/publications.pdf>

Version: 2024-02-01

48
papers

2,678
citations

257450

24
h-index

265206

42
g-index

51
all docs

51
docs citations

51
times ranked

3595
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , 2018, 9, 1416.	12.8	279
2	Iron Deficiency and Raised Hepcidin in Idiopathic Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2011, 58, 300-309.	2.8	208
3	In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. <i>Circulation</i> , 2016, 133, 1783-1794.	1.6	183
4	Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. <i>Radiology</i> , 2017, 283, 381-390.	7.3	161
5	Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. <i>Heart</i> , 2011, 97, 1054-1060.	2.9	154
6	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 135, 460-475.	1.6	154
7	Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 294-302.	5.6	153
8	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	10.7	122
9	Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 136, 2022-2033.	1.6	111
10	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 717-726.	10.7	99
11	Therapeutic targets in pulmonary arterial hypertension. <i>Circulation</i> , 2009, 121, 69-88.		80
12	Characterization of <i>GDF2</i> Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 575-585.	5.6	80
13	Human PAH is characterized by a pattern of lipid-related insulin resistance. <i>JCI Insight</i> , 2019, 4, .	5.0	69
14	Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 1770-1780.	1.6	63
15	Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 224-239.	5.6	60
16	Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. <i>Nature Communications</i> , 2020, 11, 1185.	12.8	52
17	<i>miR-21</i> /DDAH1 pathway regulates pulmonary vascular responses to hypoxia. <i>Biochemical Journal</i> , 2014, 462, 103-112.	3.7	45
18	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 586-594.	5.6	45

#	ARTICLE	IF	CITATIONS
19	Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor- β 2 in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1559-1569.	2.4	41
20	Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. , 2016, 164, 195-203.		37
21	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1102-1111.	5.6	35
22	Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. <i>Thorax</i> , 2019, 74, 380-389.	5.6	34
23	The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801805.	6.7	31
24	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. <i>European Respiratory Journal</i> , 2019, 53, 1801429.	6.7	31
25	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. <i>EBioMedicine</i> , 2021, 69, 103444.	6.1	30
26	Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, .	3.6	29
27	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. <i>Annals of the American Thoracic Society</i> , 2021, 18, 981-988.	3.2	28
28	Recent advances in pulmonary arterial hypertension. <i>F1000Research</i> , 2018, 7, 1128.	1.6	27
29	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 55, 1901486.	6.7	26
30	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2003201.	6.7	25
31	\pm 1-A680T Variant in GUCY1A3 as a Candidate Conferring Protection From Pulmonary Hypertension Among Kyrgyz Highlanders. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 920-929.	5.1	23
32	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. <i>Nature Communications</i> , 2021, 12, 7104.	12.8	21
33	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1449-1460.	5.6	19
34	Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension. <i>Circulation Research</i> , 2022, 130, 1423-1444.	4.5	19
35	The application of "omics" to pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , 2021, 178, 108-120.	5.4	18
36	Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. <i>Chest</i> , 2021, 160, 1442-1458.	0.8	17

#	ARTICLE	IF	CITATIONS
37	The pathophysiological role of novel pulmonary arterial hypertension gene<i>SOX17</i>. European Respiratory Journal, 2021, 58, 2004172.	6.7	16
38	Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 668-676.	1.2	13
39	NHLBI-CMREF Workshop Report on Pulmonary Vascular DiseaseÂClassification. Journal of the American College of Cardiology, 2021, 77, 2040-2052.	2.8	13
40	Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 81-93.	5.6	9
41	Pulmonary Hypertension: Biomarkers. Handbook of Experimental Pharmacology, 2013, 218, 77-103.	1.8	5
42	Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension. Genes, 2020, 11, 1247.	2.4	3
43	Metabolomic Insights in Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2018, 17, 103-109.	0.1	2
44	Plasma metabolomics in chronic thromboembolic pulmonary hypertension. , 2020, , .		1
45	Targeting Vessel Formation in Pulmonary Arterial Hypertension: Is the Endostatinâ€“Thrombospondin 1 Pathway a New Hope?. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 411-412.	2.9	0
46	Pathobiology of Pulmonary Hypertension. , 2022, , 530-541.		0
47	Blood biomarkers. , 2011, , 146-158.		0
48	Multi-omic profiling in pulmonary arterial hypertension. , 2020, , .		0